Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice
Insulin was first identified and isolated by Drs
This contributes to injury recovery and has the potential to boost cardiovascular health, increasing circulation and stabilizing blood pressure [33, 34, 35]
Start with 10 minutes of easy pedaling and increase gradually
US$ 23.76
US$ 22.25
US$ 22.10
US$ 20.52
US$ 22.33
US$ 29.80
US$ 29.45
US$ 20.45
US$ 29.13
US$ 20.27
